LIXT ..... Suckers are born every minute !!!
LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market
2022-04-12 10:53 ET - News Release
PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has entered into definitive agreements for the purchase and sale of 2,900,000 shares of LIXTE's common stock, at a purchase price of $2.00 per share, in a registered direct offering. The closing of the offering is expected to occur on or about April 14, 2022, subject to the satisfaction of customary closing conditions.
WestPark Capital, Inc. and WallachBeth Capital, LLC are acting as co-placement agents for the offering.